EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieÄquivalenzstudie

Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention for ST-Segment–Elevation Myocardial Infarction: A Multicenter, Randomized, Double-Blind Trial

Yan Yan iD, Jincheng Guo iD, Xiao Wang iD, Guozhong Wang, Zeyuan Fan, Delu Yin, Zhifang Wang iD, Fuchun Zhang, Changming Tian, Wei Gong, Jiamin Liu iD, Jiapeng Lu iD und 6 weitere

Circulation · 2024

DOI: 10.1161/circulationaha.123.067079 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Circulation, 2024. Verfasst von Yan Yan und 17 weiteren Autor:innen. Beteiligte Einrichtung: Center for Coronary Artery Disease (Y.Y., X.W., W.G., S.N.), Division of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, Ch…. Hauptthemen laut MEDLINE: Myocardial Infarction, Percutaneous Coronary Intervention, ST Elevation Myocardial Infarction. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Postprocedural anticoagulation (PPA) is frequently administered after primary percutaneous coronary intervention in ST-segment–elevation myocardial infarction, although no conclusive data support this practice. METHODS: The RIGHT trial (Comparison of Anticoagulation Prolongation vs no Anticoagulation in STEMI Patients After Primary PCI) was an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled, superiority trial conducted at 53 centers in China. Patients with ST-segment–elevation myocardial infarction undergoing primary percutaneous coronary intervention were randomly assigned by center to receive low-dose PPA or matching placebo for at least 48 hours. Before trial initiation, each center selected 1 of 3 PPA regimens (40 mg of enoxaparin once daily subcutaneously; 10 U·kg·h of unfractionated heparin intravenously, adjusted to maintain activated clotting time between 150 and 220 seconds; or 0.2 mg·kg·h of bivalirudin intravenously). The primary efficacy objective was to demonstrate superiority of PPA to reduce the primary efficacy end point of all-cause death, nonfatal myocardial infarction, nonfatal stroke, stent thrombosis (definite), or urgent revascularization (any vessel) within 30 days. The key secondary objective was to evaluate the effect of each specific anticoagulation regimen (enoxaparin, unfractionated heparin, or bivalirudin) on the primary efficacy end point. The primary safety end point was Bleeding Academic Research Consortium 3 to 5 bleeding at 30 days. RESULTS: Between January 10, 2019, and September 18, 2021, a total of 2989 patients were randomized. The primary efficacy end point occurred in 37 patients (2.5%) in both the PPA and placebo groups (hazard ratio, 1.00 [95% CI, 0.63 to 1.57]). The incidence of Bleeding Academic Research Consortium 3 to 5 bleeding did not differ between the PPA and placebo groups (8 [0.5%] vs 11 [0.7%] patients; hazard ratio, 0.74 [95% CI, 0.30 to 1.83]). CONCLUSIONS: Routine PPA after primary percutaneous coronary intervention was safe but did not reduce 30-day ischemic events. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03664180.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myocardial InfarctionPercutaneous Coronary InterventionST Elevation Myocardial InfarctionHumansAnticoagulantsEnoxaparinHemorrhageHeparinNeoplasm Recurrence, LocalPeptide FragmentsRecombinant ProteinsTreatment Outcome

Stichwörter der Autor:innen

ST elevation myocardial infarctionanticoagulantspercutaneous coronary intervention

Substanzen

AnticoagulantsEnoxaparinHeparinPeptide FragmentsRecombinant Proteins

Autor:innen und Institutionen

  • Center for Coronary Artery Disease (Y.Y., X.W., W.G., S.N.), Division of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
  • National Clinical Research Center of Cardiovascular Diseases, Beijing, China (Y.Y., X.W., W.G., C.M., S.N.).
  • Beijing Institute of Heart, Lung, and Blood Vessel Diseases, China (Y.Y., X.W., W.G., C.M., S.N.).
  • Beijing Luhe Hospital, Capital Medical University, Beijing, China (J.G., G.W.).
  • Civil Aviation General Hospital, Beijing, China (Z.F.).
  • The First People's Hospital of Lianyungang, Jiangsu, China (D.Y.).

ORCID-Profile: Yan Yan, Jincheng Guo, Xiao Wang, Zhifang Wang, Jiamin Liu, Jiapeng Lu, Changsheng Ma, Gilles Montalescot, Shaoping Nie

Zitieren

APA

Yan, Y., Guo, J., Wang, X., Wang, G., Fan, Z., Yin, D., Wang, Z., Zhang, F., Tian, C., Gong, W., Liu, J., Lu, J., Li, Y., Ma, C., Vicaut, E., Montalescot, G., Nie, S., & RIGHT Investigators (2024). Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention for ST-Segment–Elevation Myocardial Infarction: A Multicenter, Randomized, Double-Blind Trial. Circulation. https://doi.org/10.1161/circulationaha.123.067079

Vancouver

Yan Y, Guo J, Wang X, Wang G, Fan Z, Yin D, et al. Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention for ST-Segment–Elevation Myocardial Infarction: A Multicenter, Randomized, Double-Blind Trial. Circulation. 2024. doi:10.1161/circulationaha.123.067079

BibTeX
@article{Yan2024,
  author = {Yan, Yan and Guo, Jincheng and Wang, Xiao and Wang, Guozhong and Fan, Zeyuan and Yin, Delu and Wang, Zhifang and Zhang, Fuchun and Tian, Changming and Gong, Wei and Liu, Jiamin and Lu, Jiapeng and Li, Yongjun and Ma, Changsheng and Vicaut, Eric and Montalescot, Gilles and Nie, Shaoping and RIGHT Investigators, RIGHT Investigators},
  title = {Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention for ST-Segment–Elevation Myocardial Infarction: A Multicenter, Randomized, Double-Blind Trial},
  journal = {Circulation},
  year = {2024},
  doi = {10.1161/circulationaha.123.067079}
}
Kostenlos starten →